Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com
Niraparib Demonstrates Antitumor Activity in Heavily Pretreated mCRPC With BRCA Mutations
February 23rd 2022The PARP inhibitor niraparib elicited a meaningful overall response rate in patients with heavily pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, particularly those with BRCA alterations.
Read More
FDA Grants Orphan Drug Designation to CT103A for Relapsed/Refractory Myeloma
February 21st 2022The FDA has granted an orphan drug designation to the investigational anti-BCMA CAR T-cell therapy CT103A for use as a potential therapeutic option in patients relapsed/refractory multiple myeloma.
Read More
Addition of Lenvatinib to Pembrolizumab Fails to Improve Survival in Advanced Urothelial Carcinoma
February 18th 2022The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.
Read More
Frontline Ibrutinib/Rituximab Produced Meaningful Response Rates in Indolent MCL
February 11th 2022The combination of ibrutinib plus rituximab generated a high rate of complete response and undetectable minimal residual disease when used in the frontline treatment of patients with indolent clinical forms of mantle cell lymphoma, allowing for treatment interruption in most responders.
Read More
Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.
Read More
Imatinib/Binimetinib Combo Shows Efficacy With Manageable Safety in Treatment-Naïve Advanced GIST
February 8th 2022The combination of the TKI inhibitor imatinib and the MEK inhibitor binimetinib elicited encouraging responses in patients with treatment-naïve advanced gastrointestinal stromal tumors.
Read More
Teclistamab/Daratumumab Combo Elicits Encouraging Responses in Relapsed/Refractory Myeloma
February 7th 2022The subcutaneous combination of the BCMA-targeting bispecific antibody teclistamab and daratumumab produced promising preliminary efficacy and favorable tolerability in heavily pretreated patients with relapsed or refractory multiple myeloma, according to results from the phase 1b TRIMM-2 trial.
Read More
Frontline administration of the checkpoint inhibitors ipilimumab plus nivolumab followed by the targeted agents dabrafenib plus trametinib improved overall survival in patients with BRAF V600–mutant melanoma vs the reverse sequence of combinations, according to data from the phase 3 DREAMseq trial presented during the ASCO Virtual Plenary Series.
Read More
Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer
January 31st 2022Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.
Read More
Long-Term Data Confirm Benefit of Erdafitinib in FGFR-Mutated Urothelial Carcinoma
January 25th 2022The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations.
Read More
Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.
Read More
Venetoclax Shows Impressive Activity in Relapsed/Refractory Waldenström Macroglobulinemia
January 19th 2022Venetoclax proved to be safe and highly active when used in patients with relapsed or refractory Waldenström macroglobulinemia, including those who previously received BTK inhibitors and those harboring CXCR4 mutations.
Read More
Luspatercept Under Exploration in Myeloproliferative Neoplasm–Associated Myelofibrosis
January 17th 2022The safety and efficacy of luspatercept vs placebo is under exploration in patients with myeloproliferative neoplasm–associated myelofibrosis who are receiving concomitant JAK2 inhibitor therapy and who require red blood cell transfusions, as part of the phase 3 INDEPENDENCE trial.
Read More
Pembrolizumab Elicits Robust, Durable Antitumor Activity in MSI-H Advanced Endometrial Cancer
January 17th 2022Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.
Read More
Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia
January 14th 2022Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse effects like atrial fibrillation, hospital-diagnosed bleeding, and heart failure, but was not linked with a higher risk of acute myocardial infarction or stroke.
Read More
Zilovertamab Plus Ibrutinib Under Further Evaluation in Relapsed/Refractory MCL
January 12th 2022The FDA has agreed upon key elements, including design features and operational details, for the phase 3 ZILO-301 trial, which will evaluate zilovertamab in combination with ibrutinib in patients with relapsed or refractory mantle cell lymphoma.
Read More
CLN-081 Continues to Elicit Encouraging, Durable Responses in EGFR Exon 20 Insertion+ NSCLC
January 6th 2022CLN-081 continued to produce encouraging, durable responses with favorable safety and tolerability in patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after prior therapy.
Read More
FDA Accepts IND for RM-1995 Photoimmunotherapy in Advanced Cutaneous or Head and Neck SCC
January 6th 2022The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.
Read More
The combination of tumor-infiltrating lymphocyte cell therapy with lifileucel or LN-145 and pembrolizumab demonstrated encouraging efficacy and safety in patients with advanced melanoma, head and neck squamous cell carcinoma, and cervical cancer who were naïve to immune checkpoint inhibitors.
Read More
Addition of Lenalidomide to Rituximab Maintenance Improves PFS in Elderly Patients With MCL
December 21st 2021The addition of lenalidomide to rituximab maintenance treatment significantly improved progression-free survival compared with rituximab alone following first-line chemoimmunotherapy in patients with mantle cell lymphoma.
Read More
Itolizumab May Minimize Incidence of aGVHD Following HSCT, Improve Outcomes
December 16th 2021Itolizumab showed the potential to decrease the response of host T cells to a donor graft, minimize the incidence of acute graft-vs-host disease following hematopoietic stem cell transplantation, and improve outcomes for these patients.
Read More
Cilta-Cel Produces Deep Responses as Second-Line Treatment in Early Relapse Myeloma
December 13th 2021A single infusion of ciltacabtagene autoleucel produced early and deep responses and encouraging minimal residue disease negativity in patients with multiple myeloma who experienced early clinical relapse following initial therapy.
Read More
Cilta-cel Shows Greater Clinical Benefit Than SOC in Triple-Class Relapsed/Refractory Myeloma
December 12th 2021Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.
Read More
Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma
December 11th 2021The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.
Read More